GRAIL, Inc.

The company is a commercial-stage healthcare organization focused on multi-cancer early detection at population scale. Its core offering is Galleri, a multi-cancer early detection screening blood test designed to screen for over 50 cancer types by analyzing cell-free DNA methylation patterns and predicting the cancer signal of origin. Beyond asymptomatic population screening, the business offers a research-use-only targeted methylation platform with customizable classifiers for biopharmaceutical and oncology therapeutics partners, supporting precision oncology applications such as biomarker discovery, prognosis, and recurrence monitoring. Its customer base includes healthcare systems, self-insured employers, digital health platforms, health insurers, life insurance providers, and biopharmaceutical developers.

The company processes commercial and clinical tests through an accredited high-capacity laboratory capable of processing up to one million tests per year, having processed over 800,000 tests across clinical and commercial settings. Operating primarily in the United States, it has initiated international expansion into select markets such as Canada and Israel through distributor partnerships, with plans to enter South Korea and potential future deployment with the National Health Service in the United Kingdom. The provided text does not state the location of the company's headquarters.

Summary of the business section of Grail's latest annual report, written by StockData.

“As of December 31, 2025, we had approximately 910 full-time employees.”